KRAS and colorectal carcinoma: In metastatic CRC, ctDNA with KRAS mutations could detect diseased groups with 99.2% specificity and 87.2% sensitivity (Bettegowda et al., 2014), whereas its sensitivity to detect stage I CRC was not satisfactory.